Published in final edited form as:

Tetrahedron Lett. 2013 March 20; 54(12): 1612–1615. doi:10.1016/j.tetlet.2013.01.085.

A strategy toward the synthesis of C₁₃-oxidized cembrenolides

Alec Saitman, Steven D. E. Sullivan, and Emmanuel A. Theodorakis*

Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, United States

Abstract

An efficient strategy for the construction of C₁₃-oxidized cembrenolides is reported. Central to this strategy is the installation of the C₁₃ hydroxyl group prior to cembrane macrocyclization (via formation of the C₁–C₂ bond), allowing access to both C₁₃ alcohol epimers. The orientation of the C₁₃ alcohol was found to influence the cyclization mode of the cembranolide scaffold upon furan oxidation, leading to motifs reminiscent to bipinnatolide F, bielschowskysin, and verrillin.

Keywords

Cembrane; Macrocyclization; Furan oxidation; Anomeric effect; Hemiketal

Isolated from soft corals and octocorals, cembrenolides constitute a large family of natural products that are typified by a 14-membered cembrane skeleton. Oxidations at the periphery of this framework set the stage for various skeletal rearrangements and transannular cyclizations ultimately producing a wide array of polycyclic metabolites.¹ In addition to their ecological impact,² these compounds have been pursued both for their unusual structural motifs and for their biological and pharmacological potential.^{1a,3} For instance, oxidation at the C₁₃ center of the cembrane motif is found in several structurally intricate and biologically unexplored cembrenolides (Fig. 1).^{2a} Among them, bielschowskysin (**1**), a complex hexacyclic cembrane, was shown to exhibit very potent cytotoxicity against nonsmall cell lung cancer (EKVX, GI₅₀ ca. 10 nM) and renal cancer (CAKI-1, GI₅₀ ca. 0.5 μM).^{4,5} Moreover, **1** has demonstrated potent anti-malarial activity against *Plasmodium falciparum* (IC₅₀ ca. 10 μg/ml).⁴ Lophotoxin (**4**)⁶ was found to be a potent nicotinic acetylcholine receptor inhibitor with an LD₅₀ of 8 mg/kg^{2a} in mice and, since its isolation, it has become a synthetic conundrum.⁷ On the other hand, the bioactivities of verrillin (**2**)⁸ and bipinnatolide F (**3**)⁹ have not yet been fully explored.

Evaluation of the polycyclic motifs of bielschowskysin (**1**) and verrillin (**2**) suggests that both compounds can derive biosynthetically from the same precursor **5a** (R₁ = Me) whose cembrane macrocycle contains a furan in close proximity to a butenolide ring (Fig. 2). Furan oxidation of **5a** could produce intermediate **6** in which the electron rich enol could react with the pendant butenolide to form intermediate **7**. If the C₁₃ β-alcohol is modified as an acetate (R₂ = OAc), the resulting C₁₂ carbanion could cyclize at the C₆ center creating the strained cyclobutane motif reminiscent to that found in **1**.^{1b,c} Both photochemical^{5a–c} and Lewis-acid induced conditions¹⁰ could account for the formation of this ring. However,

© 2013 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1 858 822 0456; fax: +1 858 822 0386. etheodor@ucsd.edu (E.A. Theodorakis).

Supplementary data

Supplementary data (detailed experimental procedures, spectral characterization, and copies of ¹H and ¹³C NMR data) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2013.01.085>.

if the C₁₃ β-alcohol is available (R₂ = H), it could cyclize at the C₆ center of **7**, forming a more structurally favorable six membered hemiketal ring encountered in the motif of verrillin (**2**).

The combination of structural intricacy and biological potential of these metabolites prompted our studies toward the synthesis of the C₁₃ oxidized cembranolide **5b** (R₁ = H). From a synthetic standpoint, **5b** could derive from the union of three components: (a) a C₇–C₁₂ fragment containing a masked butenolide; (b) a C₁₃–C₁ aldehyde motif; and (c) a C₂–C₆ framework containing a furan ring.

The synthesis of **5b** began with construction of the C₇–C₁₂ fragment **11**, in which the butenolide ring is introduced as an α-selenolactone (Scheme 1).^{7d} To this end, propargyl ester **8**, available from but-3-yn-1-ol in 3 steps,¹¹ was reduced to saturated ester **9** using excess NaBH₄ and CuI¹² (Scheme 1). The crude material was then treated with cat. TsOH in benzene to form γ-lactone **10** (79% yield over two steps). It is worth noting that this approach represents a significant improvement over the previously reported synthesis of compound **10**.¹³ Treatment of **10** with LiHMDS/PhSeBr then afforded **11** in 76% yield.^{7f,13}

Aldehyde **15**, representing the C₁₃–C₁ component, was prepared beginning from propargyl alcohol **12** (Scheme 2). Methyl zirconation/iodination¹⁴ of **12** followed by protection of the pendant allylic alcohol afforded **13** in 50% combined yield. Lithiation of the resulting vinyl iodide and quenching of the reaction with oxirane yielded **14** in 55% yield.¹⁵ Oxidation of **14** with Dess–Martin periodinane¹⁶ cleanly afforded β,γ-unsaturated aldehyde **15** that was used without further purification.

The construction of the C₁₃-hydroxylated cembrenolide motif via sequential coupling of the three components is described in Scheme 3. Compound **11** was lithiated at the C₁₂ center (LiHMDS, –78 °C) and alkylated with aldehyde **15** to produce **16** as a mixture of 4 diastereomers. The crude mixture was oxidatively de-selenated^{7d,17} to afford butenolide **17** as a 1:1 mixture of C₁₃ diastereomers (**17a**, **17b**) that were easily separated by column chromatography (78% combined yield). The stereochemistry of the C₁₃ hydroxyl group was determined after macrocyclization (see Scheme 4). Protection of **17a** and **17b** with TBSCl produced the di-silylated compounds that, after selective deprotection of the primary TBS group using PPTS in ethanol,¹⁸ produced primary alcohols **18a** and **18b** (ca. 82% yield over 2 steps).

Coupling of compounds **18a** and **18b** with stannylated furfural **19** was performed via a modified Stille reaction¹⁹ (Scheme 3) to afford **20a** and **20b** in 75% average yield. Bromination of the allylic alcohol using Appel conditions²⁰ produced allylic bromides **21a** and **21b** in 88% yield. We were concerned that the presence of the new C₁₃ stereocenter, containing a bulky TBS ether on a linear uncyclized motif, might disrupt the high diastereoselectivity of the macrocyclization that has been observed in previous systems.²¹ However, to our satisfaction, this macrocyclization proceeded smoothly using CrCl₂/NiCl₂(DME) and formed compound **22a** and **22b** in 83% average yield. As was previously observed,²¹ the diastereoselectivity of this reaction is controlled by the chirality of the butenolide motif.

Removal of the extraneous silyl group was achieved using TEA-buffered HF reagent²² under microwave irradiation conditions. This treatment afforded cleanly diols **23a** and **23b** in 91% average yield. (Scheme 4). Reduction of the furylic C₂ alcohol of **23a** and **23b** with TFA and TESH gave rise to **24a** and **24b** respectively, the stereochemistry of which was determined via a single crystal X-ray analysis.²³ Epoxidation across the C₁₁–C₁₂ alkene

proceeded selectively under TBHP/Triton B conditions,²⁴ to create, irrespectively of the orientation of the adjacent C₁₃ alcohol, α -epoxides **25a** and **25b** (70% average yield).

We then explored the effect of the C₁₃ hydroxyl functionality during oxidative cyclizations of furanocembrenolides (Scheme 5).²⁵ With an eye toward the scaffold of bipinnatolide F (**3**), we treated **23b** under oxidative conditions mediated by CAN^{5c,26} (benzene/water: 20/1 at 10 °C). Unfortunately, only a complex mixture of products was observed. On the other hand, when identical oxidative conditions were applied to **23a**, containing the C₁₃-hydroxyl group at the α -face of the cembranolide scaffold, we observed the formation of 5,6-spiro ketal **27**.²³ This spiroketal motif is presumably stabilized by the diaxial orientation of the ketal oxygens (anomeric effect), despite the axial orientation of the C₁₃ butenolide side chain. Motif **27** is similar to **6**, a proposed intermediate in the biosynthesis of bielschowskysin (**1**) and verrillin (**2**),^{1b,c} where the C₆–C₇ enol ether is proposed to undergo cyclization with the C₁₁–C₁₂ butenolide to furnish the strained cyclobutane motif. Interestingly, CAN-mediated oxidation^{5c,26} of **25b** (benzene/water: 20/1 at 10 °C) led to isolation of compound **26**²³ in which an intermediate enedione, produced upon furan oxidation, underwent hemiketalization at the C₃ center by the pendant C₁₃ β -hydroxyl group. Hemiketal **26** is stabilized by the diaxial orientation of the oxygen substituents (anomeric effect)²⁷ and by the equatorial orientation of the C₁ and C₁₃ side-chains. As projected, the structure of **26** is reminiscent to that of bipinnatolide F (**3**).⁶

In conclusion, we present here an efficient strategy toward C₁₃-oxidized cembrane scaffolds that paves the way for the synthesis of complex cembrenolides. The developed approach allows construction of such scaffolds in 13 steps from readily available starting materials. Our studies suggest that the stereochemistry of the C₁₃ hydroxyl group affects the mode of cyclization upon oxidation of the furan-containing starting materials. The resulting polycyclic motifs bear structural similarities to more intricate natural products. These studies could set the stage for a divergent, biomimetic synthesis of various bioactive natural products of the cembranolide family.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the National Institutes of Health (NIH) for financial support of this work through Grant Number R01 GM081484. We thank the National Science Foundation for instrumentation Grants CHE9709183 and CHE0741968. We also thank Dr. Anthony Mrse (UCSD NMR Facility), Dr. Yongxuan Su (UCSD MS Facility) and Dr. Arnold L. Rheingold and Dr. Curtis E. Moore (UCSD X-ray Facility).

References and notes

1. For selected recent reviews see: Roethle PA, Trauner D. *Nat Prod Rep.* 2008; 25:298–317. [PubMed: 18389139] Li Y, Pattenden G. *Nat Prod Rep.* 2011; 28:429–440. [PubMed: 21212904] Li Y, Pattenden G. *Nat Prod Rep.* 2011; 28:1269–1310. [PubMed: 21637894] Lakshmi V, Kumar R. *Nat Prod Res.* 2009; 23:801–850. [PubMed: 19488923]
2. (a) Abramson SN, Fenical W, Taylor P. *Drug Dev Res.* 1991; 24:297–312. (b) Su JH, Wen ZH. *Mar Drugs.* 2011; 9:944–951. [PubMed: 21747740]
3. (a) Kamel HN, Slattery M. *Pharm Biol.* 2005; 43:253–269. (b) Ahmed AF, Shiue RT, Wang GH, Dai CF, Kuo YH, Sheu JH. *Tetrahedron.* 2003; 59:7337–7344.
4. Marrero J, Rodriguez AD, Baran P, Raptis RG, Sanchez JA, Ortega-Barria E, Capson TL. *Org Lett.* 2004; 6:1661–1664. [PubMed: 15128261]

5. (a) Doroh B, Sulikowski GA. *Org Lett*. 2006; 8:903–906. [PubMed: 16494470] (b) Miao R, Gramani SG, Lear MJ. *Tetrahedron Lett*. 2009; 50:1731–1733. (c) Nicolaou KC, Adsool VA, Hale CRH. *Angew Chem, Int Ed*. 2011; 50:5149–5152. (d) Farcet JB, Himmelbauer M, Mulzer J. *Org Lett*. 2012; 14:2195–2197. [PubMed: 22506798]
6. Fenical W, Okuda RK, Bandurraga MM, Culver P, Jacobs RS. *Science*. 1981; 212:1512–1514. [PubMed: 6112796]
7. For selected synthetic approaches towards **4** see: Tius MA, Trehan S. *J Org Chem*. 1986; 51:765–767. Paterson I, Gardner M, Banks BJ. *Tetrahedron*. 1989; 45:5283–5292. Paterson I, Brown RE. *Tetrahedron Lett*. 1999; 40:5807–5810. Wipf P, Soth MJ. *Org Lett*. 2002; 4:1787–1790. [PubMed: 12000299] Wipf P, Grenon M. *Can J Chem*. 2006; 84:1226–1241. Cases M, de Turiso FGL, Pattenden G. *Synlett*. 2001:1869–1872.
8. Rodriguez AD, Shi YP. *J Org Chem*. 2000; 65:5839–5842. [PubMed: 10970333]
9. Rodriguez AD, Shi JG, Huang SD. *J Nat Prod*. 1999; 62:1228–1237. [PubMed: 10514303]
10. (a) Ihara M, Taniguchi T, Makita K, Takano M, Ohnishi M, Taniguchi N, Fukumoto K, Kabuto C. *J Am Chem Soc*. 1993; 115:8107–8115. (b) Ihara M, Taniguchi T, Tokunaga Y, Fukumoto K. *J Org Chem*. 1994; 59:8092–8100. (c) Inanaga K, Takasu K, Ihara M. *J Am Chem Soc*. 2005; 127:3668–3669. [PubMed: 15771480]
11. (a) Roethle PA, Trauner D. *Org Lett*. 2006; 8:345–347. [PubMed: 16408911] (b) Saitman A, Rulliere P, Sullivan SDE, Theodorakis EA. *Org Lett*. 2011; 13:5854–5857. [PubMed: 21973225]
12. (a) Lin L, Zhao QY, Li AN, Ren FB, Yang FZ, Wang R. *Org Biomol Chem*. 2009; 7:3663–3665. [PubMed: 19707669] (b) Jian YJ, Wu YK. *Org Biomol Chem*. 2010; 8:811–821. [PubMed: 20135038]
13. Tang B, Bray CD, Pattenden G. *Org Biomol Chem*. 2009; 7:4448–4457. [PubMed: 19830294]
14. Negishi E, Ma SM, Sugihara T, Noda Y. *J Org Chem*. 1997; 62:1922–1923. [PubMed: 11671491]
15. Andresen G, Eriksen AB, Dalhus B, Gundersen LL, Rise F. *J Chem Soc, Perkin Trans 1*. 2001:1662–1672.
16. Dess DB, Martin JC. *J Org Chem*. 1983; 48:4155–4156.
17. Weinstabl H, Gaich T, Mulzer J. *Org Lett*. 2012; 14:2834–2837. [PubMed: 22590980]
18. Crouch RD. *Tetrahedron*. 2004; 60:5833–5871.
19. During optimization of this reaction we found that using cesium fluoride, a common additive in stannane-mediated couplings, led to decomposition of the compounds and thus, it was not used.
20. Appel R. *Angew Chem, Int Ed*. 1975; 14:801–811.
21. (a) Huang QH, Rawal VH. *Org Lett*. 2006; 8:543–545. [PubMed: 16435880] (b) Paquette LA, Astles PC. *J Org Chem*. 1993; 58:165–169. (c) Rayner CM, Astles PC, Paquette LA. *J Am Chem Soc*. 1992; 114:3926–3936.
22. Gaynor JW, Brazier J, Cosstick R. *Nucleosides Nucleotides Nucleic acids*. 2007; 26:709–712. [PubMed: 18066885]
23. CCDC 888992 (**24a**), 888994 (**24b**), 905462 (**26**), and 905463 (**27**) contain the Supplementary crystallographic data. This information can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/products/csd/request/. In the figures some hydrogen atoms have been omitted for clarity.
24. Yoshimitsu T, Nojima S, Hashimoto M, Tsukamoto K, Tanaka T. *Synthesis*. 2009; 17:2963–2969.
25. (a) Tofi M, Koltsida K, Vassilikogiannakis G. *Org Lett*. 2009; 11:313–316. [PubMed: 19072227] (b) Montagnon T, Tofi M, Vassilikogiannakis G. *Acc Chem Res*. 2008; 41:1001–1011. [PubMed: 18605738]
26. Nicolaou KC, Hale CRH, Ebner C, Nilewski C, Ahles C, Rhoades D. *Angew Chem, Int Ed*. 2012; 51:4726–4730.
27. For selected monographs see: *The Anomeric Effect and Related Stereoelectronic Effects*; Thatcher GRJ. *ACS Symposium Series*. 1993; 539. Juaristi E, Cuevas G. *Tetrahedron*. 1992; 48:5019–5087.

Figure 1.
Proposed biosynthetic pathway to bielschowskysin and verrillin.

Figure 2.
Proposed biosynthetic pathway to bielschowskysin and verrillin.

Scheme 1.

Reagents and conditions: (a) 6 equiv NaBH₄, 2 equiv CuI, MeOH, -78 °C, 15 min; (b) 0.1 equiv TsOH, PhH, 25 °C, 30 min, 79% (over 2 steps); (c) 1.1 equiv LiHMDS, -78 °C, then 1 equiv PhSeBr, THF, -78 to 25 °C, 30 min, 76%.

Scheme 2.

Reagents and conditions: (a) (i) 2.5 equiv Me_3Al , 0.2 equiv Cp_2ZrCl_2 , DCE, 25°C , 24 h, then 2.0 equiv I_2 , -40°C , 30 min, (ii) 1.1 equiv TBSCl, 3.0 equiv imid, DCM, 0°C , 1 h, 50% (over 2 steps); (b) 2.0 equiv $t\text{-BuLi}$, PhMe, -78°C , 30 min, then oxirane (excess), -78 to 25°C over 30 min, 55%; (c) 1.3 equiv Dess–Martin [O], 6.0 equiv NaHCO_3 , 25°C , 20 min, 95%.

Scheme 3.

Reagents and conditions: (a) 1.1 equiv LiHMDS, THF, -78°C , 1 h, then **15**, -78°C , 20 min; (b) 1.5 equiv H_2O_2 , 10 equiv NaHCO_3 , THF/EtOAc 1:1, 25°C , 10 min, 78% (over 2 steps); (c) (i) 1.1 equiv TBSCl, 3.0 equiv imid, DCM, 25°C , 12 h; (ii) 1.0 equiv PPTS, EtOH, 25°C , 12 h, 82% (over 2 steps); (d) 4 mol % $\text{Pd(PPh}_3)_4$, 4 mol % CuI, then **19**, DMF, 25°C , 2 h, 75%; (e) 1.1 equiv NBS, 1.1 equiv PPh_3 , DCM, -20°C , 30 min, 88%; (f) 12.0 equiv CrCl_2 , 3.0 equiv $\text{NiCl}_2(\text{DME})$, THF, 25°C , 12 h, 83%.

Scheme 4.

Reagents and conditions: (a) 5.0 equiv $\text{Et}_3\text{N}\cdot 3\text{HF}$, MeCN, mw 80 °C, 20 min, 91%; (b) 1.2 equiv TFA, 1.5 equiv TESH, DCM, 0 °C, 15 min, 81%; (c) 1.3 equiv TBHP, 0.05 equiv Triton B, THF, 0 °C, 70%.

Scheme 5.

Reagents and conditions: (a) 2.0 equiv CAN, PhH/H₂O 20:1, 0 °C, 15 min, 50%; (b) 2.0 equiv CAN, PhH/H₂O 20:1, 0 °C, 20 min, 77%.